MedTrace Logo

Tecarfarin Anti-Coagulation Trial (TACT)

NCT02522221 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2018-01-25

No results posted yet for this study

Summary

TACT is a "real world" randomized controlled trial of tecarfarin, a novel vitamin K antagonist, vs. warfarin. The quality of anticoagulation control will be compared for the two groups of subjects who require chronic oral anticoagulation for a broad panel of indications.

Conditions

Interventions

DRUG

Warfarin

Warfarin is an oral vitamin K antagonist anticoagulant.

DRUG

tecarfarin

Tecarfarin is an oral vitamin K antagonist anticoagulant

Sponsors & Collaborators

  • Espero Biopharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2019-03-30
Completion
2019-07-01
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02522221 on ClinicalTrials.gov